Patents by Inventor Christopher Logothetis

Christopher Logothetis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6517828
    Abstract: The present invention relates generally to the fields hyperproliferative disease and angiogenesis. More particularly, the present invention demonstrates that a C-CAM1 cytoplasmic domain is necessary and sufficient for inhibiting angiogenesis. In particular embodiments, it relates to inhibiting hyperproliferative cell growth by administering to a cell a C-CAM1 cytoplasmic domain or an expression construct encoding a C-CAM1 cytoplasmic domain. In other embodiments, angiogenesis is inhibited by administering to a subject a C-CAM1 polypeptide or an expression construct encoding a C-CAM1 polypeptide.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: February 11, 2003
    Assignee: Board of Regents, The University of Texas System
    Inventors: Sue-Hwa Lin, Weiping Luo, Christopher Logothetis
  • Patent number: 5728815
    Abstract: The role for a substantially purified human growth factor preparation is shown to contain a distinct polypeptide with apparent M.sub.r on SDS/PAGE of about 220 kD, and to be distinct from bFGF, with a most active fraction at about 220 kD. A human growth factor polypeptide of 157 kD was identified, in human bone marrow aspirates and from bone stromal cells, by immunoblotting with the mAb MS 329, and by affinity isolation using a MS 329 antibody column. A PSA stimulating autocrine factor, PSAF, that is precipitable in ammonium sulfate at between 60-80% saturation is able to induce PSA expression and secretion, and serves as an indicator of androgen independent prostate cell growth.
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: March 17, 1998
    Assignee: Board of Regents, The University of Texas System
    Inventors: Leland W. K. Chung, James Chan, Christopher Logothetis, Jer-Tsong Hsieh